The azelastine/fluticasone intranasal spray is a new option for treating allergic rhinoconjunctivitis. With clinical efficacy and prompt onset of action, it may be associated with increased patient satisfaction and improved medication compliance in the initial treatment period.
Allergic rhinoconjunctivitis (ARC) is a common health problem with an increasing prevalence worldwide. Self-reports from the 2007–2008 National Health Survey suggest that it affects approximately 15% of the Australian population. In a population-based study conducted in Tasmania in 1991-93, the reported prevalence of hayfever in an adult cohort was 41%.
Picture credit: © Tim Vernon, LTH NHS Trust/SPL.